Literature DB >> 30361925

Age effects on basic symptoms in the community: A route to gain new insight into the neurodevelopment of psychosis?

Frauke Schultze-Lutter1,2, Stephan Ruhrmann3, Chantal Michel4, Jochen Kindler4, Benno G Schimmelmann4,5, Stefanie J Schmidt4,3,6.   

Abstract

Reports of limited clinical significance of attenuated psychotic symptoms before age 15/16 indicate an important role of neurodevelopment in the early detection of psychoses. Therefore, we examined if age also exerts an influence on the prevalence and clinical significance of the 14 cognitive and perceptive basic symptoms (BS) used in psychosis-risk criteria and conceptualized as the most direct self-experienced expression of neurobiological aberrations. A random representative general population sample of the Swiss canton Bern (N = 689, age 8-40 years, 06/2011-05/2014) was interviewed for BS, psychosocial functioning, and current mental disorder. BS were reported by 18% of participants, mainly cognitive BS (15%). In regression analyses, age affected perceptive and cognitive BS differently, indicating an age threshold for perceptive BS in late adolescence (around age 18) and for cognitive BS in young adulthood (early twenties)-with higher prevalence, but a lesser association with functional deficits and the presence of mental disorder in the below-threshold groups. Thereby, interaction effects between age and BS on functioning and mental disorder were commonly stronger than individual effects of age and BS. Indicating support of the proposed "substrate-closeness" of BS, differential age effects of perceptual and cognitive BS seem to follow normal brain maturation processes, in which they might occur as infrequent and temporary non-pathological disturbances. Their persistence or occurrence after conclusion of main brain maturation processes, however, might signify aberrant maturation or neurodegenerative processes. Thus, BS might provide important insight into the pathogenesis of psychosis and into differential neuroprotective or anti-inflammatory targets.

Entities:  

Keywords:  Age; Basic symptoms; Brain development; Epidemiology; Neuropsychopathology; Psychosis

Mesh:

Year:  2018        PMID: 30361925      PMCID: PMC7069926          DOI: 10.1007/s00406-018-0949-4

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  4 in total

1.  An ecological momentary assessment study of age effects on perceptive and non-perceptive clinical high-risk symptoms of psychosis.

Authors:  C Michel; S Lerch; J R Büetiger; R Flückiger; M Cavelti; J Koenig; M Kaess; J Kindler
Journal:  Eur Child Adolesc Psychiatry       Date:  2022-05-18       Impact factor: 5.349

2.  Effects of age and sex on clinical high-risk for psychosis in the community.

Authors:  Frauke Schultze-Lutter; Benno G Schimmelmann; Rahel Flückiger; Chantal Michel
Journal:  World J Psychiatry       Date:  2020-05-19

3.  Spontaneous discontinuation of distressing auditory verbal hallucinations in a school-based sample of adolescents: a longitudinal study.

Authors:  Vera Brink; Catheleine van Driel; Saliha El Bouhaddani; Klaas J Wardenaar; Lieke van Domburgh; Barbara Schaefer; Marije van Beilen; Agna A Bartels-Velthuis; Wim Veling
Journal:  Eur Child Adolesc Psychiatry       Date:  2019-08-27       Impact factor: 4.785

4.  The impact of visual dysfunctions in recent-onset psychosis and clinical high-risk state for psychosis.

Authors:  Johanna M Schwarzer; Inga Meyhoefer; Linda A Antonucci; Lana Kambeitz-Ilankovic; Marian Surmann; Olga Bienek; Georg Romer; Udo Dannlowski; Tim Hahn; Alexandra Korda; Dominic B Dwyer; Anne Ruef; Shalaila S Haas; Marlene Rosen; Theresa Lichtenstein; Stephan Ruhrmann; Joseph Kambeitz; Raimo K R Salokangas; Christos Pantelis; Frauke Schultze-Lutter; Eva Meisenzahl; Paolo Brambilla; Alessandro Bertolino; Stefan Borgwardt; Rachel Upthegrove; Nikolaos Koutsouleris; Rebekka Lencer
Journal:  Neuropsychopharmacology       Date:  2022-08-18       Impact factor: 8.294

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.